Compare TWN & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TWN | AGMB |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Belgium |
| Employees | N/A | 62 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.8M | 562.4M |
| IPO Year | 1994 | N/A |
| Metric | TWN | AGMB |
|---|---|---|
| Price | $93.89 | $12.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 56.9K | ★ 124.1K |
| Earning Date | 01-01-0001 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.03 | $8.75 |
| 52 Week High | $105.09 | $17.82 |
| Indicator | TWN | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 52.66 |
| Support Level | $88.51 | $9.54 |
| Resistance Level | $102.77 | $12.83 |
| Average True Range (ATR) | 3.70 | 1.74 |
| MACD | -0.66 | 0.20 |
| Stochastic Oscillator | 21.40 | 38.16 |
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.